|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Immunomedics
Pharmacyclics
|
|
gptkbp:awards
|
Fortune 500
Best Places to Work
S&P 500
Forbes_World's_Most_Innovative_Companies
|
|
gptkbp:CEO
|
gptkb:Daniel_O'Day
|
|
gptkbp:clinicalTrials
|
HIV clinical trials
HIV treatments
Hepatitis C treatments
oncology treatments
oncology clinical trials
Hepatitis C clinical trials
inflammation clinical trials
inflammatory diseases treatments
COVID-19_clinical_trials
|
|
gptkbp:employees
|
over 12,000
|
|
gptkbp:focus
|
antiviral drugs
|
|
gptkbp:founded
|
1987
|
|
gptkbp:headquarters
|
gptkb:Foster_City,_California,_USA
gptkb:Foster_City,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gilead Sciences GmbH
|
|
gptkbp:investmentFocus
|
$1 billion in research and development
$100 million in inflammation research
$200 million in COVID-19 research
$300 million in oncology research
$500 million in HIV research
|
|
gptkbp:market
|
$80 billion (2021)
|
|
gptkbp:netIncome
|
$6.2 billion (2020)
|
|
gptkbp:notableEvent
|
gptkb:Atripla
gptkb:Sovaldi
gptkb:Truvada
Biktarvy
Remdesivir
Harvoni
|
|
gptkbp:partnerships
|
gptkb:Galapagos_NV
gptkb:GSK
gptkb:AstraZeneca
gptkb:Bristol-Myers_Squibb
gptkb:Merck_&_Co.
|
|
gptkbp:philanthropy
|
gptkb:Gilead_Global_Health_Initiative
gptkb:Gilead_COMPASS_Initiative
gptkb:Gilead_Foundation
gptkb:Gilead_HIV_Research_Initiative
Gilead's_COVID-19_Response
Gilead's_Global_Health_Initiative
Gilead's_HIV_Cure_Research_Initiative
Gilead_Access_Program
|
|
gptkbp:researchAreas
|
HIV
Hepatitis C
oncology
inflammation
Hepatitis B
|
|
gptkbp:revenue
|
$24.4 billion (2020)
|
|
gptkbp:stockSymbol
|
gptkb:GILD
|
|
gptkbp:subsidiary
|
gptkb:Gilead_Sciences_UK_Ltd.
gptkb:Gilead_Sciences_Singapore_Pte._Ltd.
gptkb:Gilead_Sciences_Ireland_UC
gptkb:Gilead_Sciences_Canada,_Inc.
gptkb:Gilead_Sciences_Australia_Pty_Ltd.
Gilead_Sciences_GmbH_(Germany)
|
|
gptkbp:website
|
www.gilead.com
|